echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > ENHERTU, AN ANTIbody drug conjugated with HER2, has been awarded the FDA's breakthrough therapy title to treat HER2-positive metastatic non-small cell lung cancer

    ENHERTU, AN ANTIbody drug conjugated with HER2, has been awarded the FDA's breakthrough therapy title to treat HER2-positive metastatic non-small cell lung cancer

    • Last Update: 2020-05-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    AstraZeneca and Daiichi Sankyo's target HER2 antibody drug conjugated ENHERTU (FAM-trastustudeuxtecan-nxki) earned the U.SFood and Drug Administration's (FDA) breakthrough therapy designation (BTD) for treating HER2-positive metastatic non-small cell lung cancer (NSCLC)in December, Enhertu was approved by the FDA for the first time to treat patients who had previously received two or more metastatic HER2-positive breast cancers based on anti-HER2 therapyEnhertu has been awarded the FDA's BTD title for three types of cancer, which this week also earned the TITLE of HER2-positive metastatic gastric or gastroesophageal cobdiseasepreviously received the TITLE of HER2-positive breast cancer, prompting Enhertu to accelerate approval for her2-positive breast cancer in DecemberSix key trials of Enhertu are currently under way worldwide, involving a variety of HER2-positive cancers, such as breast, stomach and lung cancer, according to First Three PharmaceuticalsTrials of Enhertu's joint use with other anti-cancer therapies, including immunotherapy, are also under way
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.